We are live on ! Find out more
AIM

Arcadia Investment Management Portfolio holdings

AUM $584M
1-Year Est. Return 21.44%
This Fund
S&P 500
This Quarter Est. Return
+10.3%
1 Year Est. Return
+21.44%
3 Year Est. Return
+83.48%
5 Year Est. Return
+113.71%
10 Year Est. Return
+434.1%
AUM
$422M
AUM Growth
+$38.6M
Cap. Flow
+$1.43M
Cap. Flow %
0.34%
Top 10 Hldgs %
28.92%
Holding
117
New
5
Increased
29
Reduced
46
Closed
2

Sector Composition

Rank Sector Weight
1 Technology 17.21%
2 Healthcare 16.03%
3 Consumer Discretionary 15.38%
4 Industrials 14.34%
5 Financials 10.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ZBRA icon
101
Zebra Technologies
ZBRA
$17.8B
$242K 0.06%
4,475
BP icon
102
BP
BP
$107B
$241K 0.06%
6,061
-612
-9% -$22.8K
XYL icon
103
Xylem
XYL
$28.1B
$226K 0.05%
+6,534
New +$210K
MCD icon
104
McDonald's
MCD
$195B
$221K 0.05%
2,273
FISV
105
Fiserv Inc
FISV
$27.9B
$207K 0.05%
+7,000
New +$189K
CSCO icon
106
Cisco
CSCO
$479B
$206K 0.05%
9,175
-2,100
-19% -$46.5K
SPLS
107
DELISTED
Staples Inc
SPLS
$203K 0.05%
12,788
DIS icon
108
Walt Disney
DIS
$181B
$201K 0.05%
+2,625
New +$182K
CWCO icon
109
Consolidated Water Co
CWCO
$488M
$200K 0.05%
14,159
TEVA icon
110
Teva Pharmaceuticals
TEVA
$41.2B
-53,084
Closed -$2.01M

Similar funds

Arcadia Investment Management's Q4 2013 Portfolio in Review

As of Q4 2013, Arcadia Investment Management held 117 positions worth $422M, up 10% from $384M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Arcadia Investment Management's Q4 2013 filing shows 5 new, 29 increased, 46 reduced and 2 closed positions. Its largest new stake was Haemonetics: 10,400 shares worth $438K. The largest sale was Teva Pharmaceuticals, an estimated $2.01M.

By sector, the portfolio is most concentrated in Technology at 17% of assets, up from 17% a quarter earlier, followed by Healthcare and Consumer Discretionary.

  • Arcadia Investment Management's largest Q4 2013 buy was Haemonetics: 10,400 shares worth $438K.
  • Arcadia Investment Management added most to Viatris in Q4 2013, an estimated $2.92M increase.
  • Arcadia Investment Management's biggest Q4 2013 reduction was O'Reilly Automotive, cutting an estimated $468K.
  • Arcadia Investment Management fully exited Teva Pharmaceuticals in Q4 2013, selling an estimated $2.01M.
  • Arcadia Investment Management's ten largest holdings make up 29% of its $422M portfolio in Q4 2013.
  • Arcadia Investment Management opened 5 new positions and closed 2 in Q4 2013.
  • Arcadia Investment Management's portfolio value rose 10% quarter-over-quarter to $422M.

Based on Arcadia Investment Management's 13F filing for Q4 2013, filed 6 Feb 2014.